Alnylam has updated this opportunity with a new deadline of May 29, 2026, and increased the maximum funding to $250,000 per proposal. Your application should now focus specifically on advancing clinical decision-making in ATTR-CM. Be sure to review the updated application requirements, which now ask for sustainability plans, honoraria policies, and a detailed project timeline.
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal submission)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; actual award may vary from request.
Summary: Supports independent educational initiatives to advance clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM), with emphasis on practical, real-world impact for healthcare professionals.
Key Information: Applicants must be organizations (not individuals); ACCME accreditation required for medical education providers.